References
- NCCNClinical Practice Guidelines in Oncology: Kidney Cancer2015 Version 1. Available from: http://www.nccn.org/professionals/physician_gls/pdf/kidney.pdfAccessed August 28, 2017
- LjungbergBBensalahKCanfieldSEAU guidelines on renal cell carcinoma: 2014 updateEur Urol201567591392425616710
- EscudierBPortaCSchmidingerMRenal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-upAnn Oncol201425suppl 3iii49iii5625210086
- AlimohamedNLeeJLSrinivasSA population-based overview of sequences of targeted therapy in metastatic renal cell carcinomaClin Genitourin Cancer2014124e127e13124485801
- KoJJChoueiriTKRiniBIFirst-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDCBr J Cancer201411081917192224691425
- HengDYSignorovitchJSwallowEComparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: a systematic review and meta-analysis of real-world observational studiesPLoS One2014912e11426425493562
- BergmannLKubeUDoehnCEverolimus in metastatic renal cell carcinoma after failure of initial anti-VEGF therapy: final results of a noninterventional studyBMC Cancer20151530325925846
- CalvoEEscudierBMotzerRJEverolimus in metastatic renal cell carcinoma: subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 studyEur J Cancer201248333333922209391
- MotzerRJAlyasovaAYeDPhase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4)Ann Oncol201627344144826681676
- AlbigesLKubeUEymardJCEverolimus for patients with metastatic renal cell carcinoma refractory to anti-VEGF therapy: results of a pooled analysis of non-interventional studiesEur J Cancer201551162368237426276039
- KontovinisLLaschosKKaradimouASequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical studyMed Oncol201229275075421279702
- RiniBIEscudierBTomczakPComparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialLancet201137898071931193922056247
- SternbergCNDavisIDMardiakJPazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trialJ Clin Oncol20102861061106820100962
- MotzerRJHutsonTECellaDPazopanib versus sunitinib in metastatic renal-cell carcinomaN Engl J Med2013369872273123964934
- EscudierBPortaCBonoPRandomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES StudyJ Clin Oncol201432141412141824687826
- MotzerRJEscudierBOudardSRavaudARECORD-1 Study GroupEfficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialLancet2008372963744945618653228
- HengDYChoueiriTKRiniBIOutcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trialsAnn Oncol201425114915424356626
- MotzerRJBacikJSchwartzLHPrognostic factors for survival in previously treated patients with metastatic renal cell carcinomaJ Clin Oncol200422345446314752067
- ChoueiriTKEscudierBPowlesTMETEOR InvestigatorsCabozantinib versus everolimus in advanced renal-cell carcinomaN Engl J Med2015373191814182326406150
- MotzerRJEscudierBMcDermottDFCheckMate 025 InvestigatorsNivolumab versus everolimus in advanced renal-cell carcinomaN Engl J Med2015373191803181326406148
- MotzerRJHutsonTEGlenHLenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trialLancet Oncol201516151473148226482279
- VogelzangNJHackshawMDHutsonTEFirst-line and sequential use of pazopanib followed by mammalian target of rapamycin inhibitor therapy among patients with advanced renal cell carcinoma in a US community oncology settingClin Genitourin Cancer201513321021725498215
- BellmuntJPonsFForeshewASequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicityClin Genitourin Cancer201412426226924795159
- MotzerRJHutsonTEMcCannLDeenKChoueiriTKOverall survival in renal-cell carcinoma with pazopanib versus sunitinibN Engl J Med2014370181769177024785224
- SoerensenAVDonskovFHermannGGImproved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: results from the Danish Renal Cancer Group (DARENCA) study-2Eur J Cancer201450355356224215846
- HengDYXieWReganMMPrognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter studyJ Clin Oncol200927345794579919826129
- BamiasATzannisKPapatsorisAPrognostic significance of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma treated with first-line sunitinib: a European multi-institutional studyClin Genitourin Cancer201412537338324819319
- BamiasATzannisKBeuselinckBDevelopment and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaborationBr J Cancer2013109233234123807171
- BamiasABonoPProcopioGPRINCIPAL: a prospective observational study of real-world treatment patterns and treatment outcomes in patients with advanced or metastatic renal cell carcinoma (mRCC) receiving pazopanibJ Clin Oncol2014325s sul;abstrTS4600^
- ChenCCHessGPLiuZSecond-line treatment outcomes after first-line sunitinib therapy in metastatic renal cell carcinomaClin Genitourin Cancer201210425626122682982
- BuchlerTBortlicekZPoprachAEfficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: a registry-based analysisUrol Oncol201432556957524629497
- GrunwaldVKarakiewiczPIBavbekSEREACT Study GroupAn international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapyEur J Cancer201248332433221803569
- EscudierBMichaelsonMDMotzerRJAxitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trialBr J Cancer2014110122821282824823696
- PowlesTStaehlerMLjungbergBUpdated EAU guidelines for clear cell renal cancer patients who fail VEGF targeted therapyEur Urol20166914626508312